A Phase 2 Study of Eribulin in Patients With HER2-Negative, Metastatic Breast Cancer: Evaluation of Efficacy, Toxicity and Patient-Reported Outcomes
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 27 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 10 Jun 2017 Biomarkers information updated
- 06 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.